Compound hub · Retatrutide
How long has retatrutide been studied?
The first dated human work on retatrutide began on 18 December 2019. That is when enrollment opened for a first-stage safety trial in people with type 2 diabetes (Urva et al., The Lancet, 2022; NCT04143802). Retatrutide has since entered large late-stage (Phase 3) testing. ClinicalTrials.gov NCT05929066 lists the TRIUMPH-1 trial as starting on 10 July 2023.
Form Labs materials are research reference materials, not the approved medicines; no Form Labs product is approved for human or veterinary use.
01How longContents
You have felt a meal land. About twenty minutes after the first bite, something in you decides you have had enough. That feeling has chemistry behind it. Your gut sends messages to your brain every time you eat. A molecule built to work with those messages makes headlines, and the natural question is whether anyone has studied it, and for how long.
This page is part of the retatrutide hub. It answers that question with dates. Retatrutide's record lives in two places. Trial registries stamp when people enrolled. Journals stamp when results went public. Side by side, they give a clear timeline, from a December 2019 enrollment window to a Phase 3 programme maturing in 2026.
- Guidethe retatrutide hubRetatrutide research hub: what the compound is, which receptor systems the literature maps it to, what the published trials measured, and how it compares with approved medicines.
Key facts
| Common name | retatrutide |
|---|---|
| Research code | LY3437943 |
| Developer | Eli Lilly |
| CAS | 2381089-83-2 |
| First characterisation paper | Coskun et al., Cell Metabolism, 2022 |
| Earliest dated human enrollment | 18 December 2019 (NCT04143802) |
| Phase 2 obesity trial published | 26 June 2023 (New England Journal of Medicine) |
| Phase 3 obesity trial start | 10 July 2023 (TRIUMPH-1, NCT05929066) |
| TRIUMPH-1 study completion | 30 April 2026 (registry, actual) |
| First peer-reviewed Phase 3 paper | Bajaj et al., The Lancet, June 2026 (TRANSCEND-T2D-1) |
| Dated human research span | December 2019 – August 2026 |
| Trial phase as of 2026 | Phase 3 |
| Approval as of 2026 | Approved in no country |
How long has retatrutide been studied?
Retatrutide's earliest dated human enrollment is 18 December 2019. It was a Phase 1b multiple-ascending-dose trial. That is a first-stage safety trial in which each group of volunteers got a series of slowly larger doses (Urva et al., The Lancet, 2022; NCT04143802). The compound was first described in public in 2022 (Coskun et al., Cell Metabolism, 2022). The retatrutide research guide traces the record from there. So dated human research runs from December 2019 to 2026. As of 2026 retatrutide is in Phase 3 trials.
Two kinds of date matter here, and they answer different questions. A registry date shows when a trial enrolled people. A publication date shows when the world could read about it. Retatrutide's registry record reaches back to December 2019. Its first journal paper came out in 2022. So the compound was under study in people for nearly three years before its name appeared in print. Both dates are real. They measure different things.
GuideThe retatrutide research guideA plain-English guide to LY3437943: what it is, the three receptor systems, what each trial phase found, and where the evidence stops.
Evidence limits
What does the research record not show?
Retatrutide's research record has four gaps. First, no first-synthesis or first-lab date is published. The year 2022 marks the first paper describing the compound (Coskun et al., Cell Metabolism, 2022). It is not a discovery date. Second, no enrollment window is dated for the first single-dose study in people. The earliest dated human start is 18 December 2019, when Phase 1b multiple-ascending-dose enrollment opened (Urva et al., The Lancet, 2022). Third, no peer-reviewed outcomes paper exists for the Phase 3 obesity programme as of 2026. TRIUMPH-1 shows 'No Results Posted' on ClinicalTrials.gov (NCT05929066). Fourth, no regulator has approved retatrutide in any country as of 2026.
Two widely quoted figures need their labels kept on. The 80-week and 104-week TRIUMPH-1 weight-change numbers are a company topline that Eli Lilly released on 21 May 2026. That is a press release, not a peer-reviewed result. The often-cited 24.2% body-weight change is the 48-week result for the 12-mg group. It is a least-squares mean, which is an average adjusted by a model, from 338 adults (Jastreboff et al., NEJM, 2023). It is not the 24-week primary endpoint of that trial.
Comparisons also run ahead of the evidence. No published head-to-head trial of retatrutide against tirzepatide or semaglutide exists as of 2026. TRIUMPH-5 (NCT06662383) is listed as active and not recruiting. The one published Phase 3 paper is TRANSCEND-T2D-1 (Bajaj et al., The Lancet, 2026). It is a 40-week trial in type 2 diabetes with retatrutide on its own, not added to another medicine. It is not the obesity Phase 3 package. The day-43 body-weight result in the first paper on the compound (Coskun et al., Cell Metabolism, 2022) is a single-dose Phase 1 measure of what the body did after one dose. It is not an efficacy result.
Even the headcounts differ. The TRIUMPH-1 registry entry lists 2,335 participants enrolled. Eli Lilly's 21 May 2026 company topline reports 2,339 randomised. The two figures come from different counting points, so they are not interchangeable. The record does not explain the gap, and neither does this article.
When did retatrutide first enter human trials?
Retatrutide's first dated human trial opened enrollment on 18 December 2019. That Phase 1b multiple-ascending-dose trial enrolled 72 people with type 2 diabetes. Enrollment closed on 28 December 2020. The trial reported a half-life of about six days. The paper says this supports a once-weekly schedule (Urva et al., The Lancet, 2022). An earlier Phase 1 single-ascending-dose study appears in the first paper on the compound (Coskun et al., Cell Metabolism, 2022). That record does not date its enrollment window. So 18 December 2019 stays the earliest dated human enrollment on record.
Read the two Phase 1 studies as a pair. The undated one came first, and the dated one built on it. Early safety work often shows up later in a paper that describes the compound. That is how the single-ascending-dose data reached print in 2022 (Coskun et al., Cell Metabolism, 2022). The record does not let us turn that gap into a date. Human work on retatrutide was under way by 18 December 2019, and probably earlier, but the earlier part is undated. The Phase 1b paper also recorded a week-12 body-weight change of up to −8.96 kg in the 3/6/9/12-mg group, after the placebo group's change was subtracted (Urva et al., The Lancet, 2022). The 90% confidence interval is the range the true figure most likely falls in. It ran from −11.16 to −6.75. That is a signal seen over twelve weeks inside a safety trial. It is not a verdict on efficacy.
What did the Phase 2 trials measure?
Two Phase 2 trials of retatrutide reported in 2023. In the obesity trial, 338 adults were followed for 48 weeks. The 12-mg group averaged a 24.2% body-weight change, against 2.1% on placebo (Jastreboff et al., New England Journal of Medicine, 2023). The primary endpoint of that trial was the 24-week change. So 24.2% is a 48-week figure, not the primary result. The diabetes trial randomised 281 participants across 42 US centres. HbA1c is a three-month blood-sugar marker. It changed by 2.02 points to 24 weeks in the 12-mg escalation arm, against 0.01 on placebo (Rosenstock et al., The Lancet, 2023).
A percentage only means something when it stays tied to the trial that produced it. So the details matter: 48 weeks, 338 adults, the 12-mg arm, and a placebo group that barely moved. At 48 weeks that same 12-mg group reached a body-weight change of 5% or more in 100% of participants, 10% or more in 93%, and 15% or more in 83%. On placebo the figures were 27%, 9% and 2% (Jastreboff et al., NEJM, 2023). The diabetes trial tells its own story. Body weight at 36 weeks changed by −16.94% against −3.00% on placebo. The dulaglutide 1.5-mg comparator arm had an HbA1c change of −1.41 points (Rosenstock et al., The Lancet, 2023).
Numbers like these invite a league table. The fair version of that comparison puts the same molecule beside approved medicines, states its criteria and ranks nothing. It lives in how retatrutide, Mounjaro, and Ozempic differ.
- Guidehow retatrutide, Mounjaro, and Ozempic differRetatrutide, Mounjaro, and Ozempic compared by molecule, receptor systems, and approval status. Research material is not a medicine.
What stage is retatrutide at in 2026?
Retatrutide is in Phase 3 obesity trials as of 2026. They run under one master protocol, which is a single trial design covering several sub-studies. It is registered as TRIUMPH-1 (ClinicalTrials.gov NCT05929066). The registry entry records an actual study start of 10 July 2023, an enrollment of 2,335 participants, and an actual study completion of 30 April 2026. The results tab shows 'No Results Posted'. Eli Lilly shared 80-week topline figures in a company press release on 21 May 2026. That is a company topline, not a peer-reviewed trial result. The protocol pairs an 80-week main period with a 24-week extension. The registry records an actual primary completion of 6 April 2026.
The topline figures come from Eli Lilly's 21 May 2026 company press release, not a journal. The release reports an 80-week efficacy estimand. That is the exact quantity a trial sets out to estimate. The average baseline was 112.7 kg (BMI 40.0). Mean body-weight reductions were −28.3% in the 12-mg arm, −25.9% in the 9-mg arm and −19.0% in the 4-mg arm, against −2.2% on placebo. A company topline arrives before the methods paper does. So these numbers sit in a different class of evidence from everything in the citations list.
The registry cannot smooth out one wrinkle. ClinicalTrials.gov NCT05929066 lists 2,335 participants enrolled, while the 21 May 2026 Lilly company topline says 2,339 were randomised. Enrollment and randomisation are different counting points. Neither source explains the gap, and both figures stand.
Has any Phase 3 result been published in a journal?
One Phase 3 trial of retatrutide has been published in a journal as of 2026. TRANSCEND-T2D-1 ran for 40 weeks in 537 adults with type 2 diabetes. Their blood sugar was not controlled by diet and exercise alone (Bajaj et al., The Lancet, 2026). The trial ran across 48 sites. People were randomised to one of three retatrutide arms or to placebo. It measured blood-sugar control, not obesity outcomes, so it sits outside the TRIUMPH obesity programme. The Phase 3 results for the obesity programme have not appeared in a journal.
TRANSCEND-T2D-1 randomised its 537 participants to the 4-mg, 9-mg and 12-mg arms or to placebo. The groups held 134, 133, 136 and 134 people. Of the 537, 490 finished on drug, which is 91% (Bajaj et al., The Lancet, 2026). The same paper records HbA1c changes of −1.69%, −1.86% and −1.94% across the three retatrutide arms, against −0.81% on placebo. Body-weight changes were −11.5%, −13.9% and −15.3%, against −2.6%. This is a solid, peer-reviewed Phase 3 result. It aims at blood sugar in type 2 diabetes, which is a different question from the one TRIUMPH-1 asks.
Is retatrutide approved anywhere?
Retatrutide holds no regulatory approval in any country as of 2026. The FDA, the TGA and every other regulator have not approved it. It remains an investigational compound. Research material is not a medicine, is not a substitute for one, and is not for human or animal use. Approval needs a finished Phase 3 evidence package that a regulator has assessed. The obesity Phase 3 registry entry shows no results posted as of 2026 (ClinicalTrials.gov NCT05929066).
What legally exists is laboratory reference material, sold for research use. Form Laboratories lists retatrutide reference material as freeze-dried laboratory stock, which is not a medicine. Reading laboratory paperwork is its own skill. It covers what a certificate records, what a third-party report can and cannot prove, and how a batch stays traceable. The quality and verification hub walks through it.
Research use onlyRetatrutideIn stockretatrutide reference material
GuideThe quality and verification hubHow research peptides are tested and verified: purity methods, certificates of analysis, batch traceability, and what each document can and cannot tell you.
Comparison
Dated record as of 2026: registry and journal dates only. Undated events are marked as such. This table is not a forecast.
| Date | Event | Source |
|---|---|---|
| 18 December 2019 | Phase 1b multiple-ascending-dose enrollment opens; earliest dated human enrollment | Urva et al., The Lancet, 2022; NCT04143802 |
| 28 December 2020 | Phase 1b enrollment closes | Urva et al., The Lancet, 2022 |
| September 2022 | First public characterization of LY3437943, with Phase 1 single-ascending-dose data (epub August 2022) | Coskun et al., Cell Metabolism, 2022 |
| November 2022 | Phase 1b multiple-ascending-dose trial published | Urva et al., The Lancet, 2022 |
| 26 June 2023 | Phase 2 obesity trial published (epub); first paper using the name retatrutide | Jastreboff et al., NEJM, 2023 |
| 10 July 2023 | TRIUMPH-1 actual study start | ClinicalTrials.gov NCT05929066 |
| August 2023 | Phase 2 type 2 diabetes trial published | Rosenstock et al., The Lancet, 2023 |
| 6 April 2026 | TRIUMPH-1 actual primary completion | ClinicalTrials.gov NCT05929066 |
| 30 April 2026 | TRIUMPH-1 actual study completion | ClinicalTrials.gov NCT05929066 |
| 21 May 2026 | Eli Lilly company topline on TRIUMPH-1 (press release, not a paper) | Eli Lilly & Co. press release |
| June 2026 | TRANSCEND-T2D-1 published; first peer-reviewed Phase 3 paper | Bajaj et al., The Lancet, 2026 |
FAQ
How long has retatrutide been studied?
Dated human research on retatrutide runs from 18 December 2019, when Phase 1b enrollment opened (Urva et al., The Lancet, 2022), to 2026. The first public description came in 2022 (Coskun et al., Cell Metabolism, 2022). No first-synthesis date is published.
When did retatrutide Phase 3 trials start?
Retatrutide's Phase 3 obesity programme opened on 10 July 2023. That is the actual study start date logged for TRIUMPH-1 (ClinicalTrials.gov NCT05929066). The registry shows the trial as finished on 30 April 2026.
What is TRIUMPH-1?
TRIUMPH-1 is the Phase 3 obesity master protocol for retatrutide. It enrolled 2,335 participants, with an 80-week main period plus a 24-week extension (ClinicalTrials.gov NCT05929066). The registry shows no results posted as of 2026.
Is retatrutide approved?
No. As of 2026 no regulator anywhere has approved retatrutide. It remains an investigational compound in Phase 3 trials.
Have retatrutide Phase 3 results been published?
One retatrutide Phase 3 trial has been published. It is TRANSCEND-T2D-1, a 40-week trial in type 2 diabetes (Bajaj et al., The Lancet, 2026). The obesity Phase 3 results remain unpublished as of 2026.
More in this hub
- GuideRetatrutideRetatrutide research hub: what the compound is, which receptor systems the literature maps it to, what the published trials measured, and how it compares with approved medicines.
- GuideRetatrutide vs Mounjaro vs Ozempic: what's the difference?Retatrutide, Mounjaro, and Ozempic compared by molecule, receptor systems, and approval status. Research material is not a medicine.
- GuideWhat is the difference between GLP-1 and GLP-3?GLP-1 is a natural gut hormone. GLP-3 is a nickname. Learn what GLP-1, GIP and glucagon receptors mean, and what names alone cannot show.
- GuideIs retatrutide available in the USA? What the public record saysRetatrutide's US approval record, checked 17 October 2026. Read FDA statements and Lilly's filing plan. A trial listing does not mean medicine approval.
- GuideHow much does retatrutide cost? Is there an approved price?The checked records give no price for retatrutide as an approved medicine. Learn what approval, a maker's price and a PBS listing each mean.
- GuideWhat does retatrutide do in the body? The three receptors in the papersRetatrutide papers name three cell receivers: GIP, GLP-1 and glucagon receptors. Learn what cell tests and human trials measure, and what each cannot show.
- GuideHow are people getting retatrutide? Trials, approval and research supplyWhat trial records and medicine checks say about retatrutide access and research-only labels. Dated facts, without buying or personal-use advice.
- GuideWho should not take retatrutide? What the trial exclusion lists sayWho was left out of retatrutide trials? Read how TRIUMPH entry rules differ and why these lists cannot show personal safety.
- GuideWhat makes a peptide company reputable? How to check a supplier's testingCheck a peptide supplier's batch records and test reports. Learn what purity tests, mass tests and outside labs can show.
- GuideWhat is replacing tirzepatide? Weight-loss medicines in Phase 3 in 2026A dated look at retatrutide, CagriSema, survodutide and VK2735. Read about their targets, Phase 3 studies and what the records cannot show.
- GuideRetatrutide and type 2 diabetes: what the trials measuredWhat retatrutide diabetes trials measured. Read about HbA1c, the Lancet Phase 2 paper and TRANSCEND-T2D study plans. Check dated study records and limits.
- GuideRetatrutide pharmacokinetics: what is the half-life?Retatrutide's pharmacokinetics as published in two early human studies, what each study enrolled and measured, and what has not been measured. Research material is not a medicine.
- GuideRetatrutide Phase 2 trial: what did the paper find?A guided read of the retatrutide Phase 2 obesity trial (NEJM 2023): 338 adults, 48 weeks, and what the primary end point actually measured.
- GuideWhat is the molecular formula of retatrutide?Retatrutide molecular formula: C221H342N46O68, the registry record it comes from, and what a count of atoms cannot prove. Research use only.
- GuideNCT05882045: what is the TRIUMPH-3 retatrutide trial?NCT05882045 is TRIUMPH-3, a Phase 3 retatrutide trial in obesity with cardiovascular disease. Registry status, enrolment, endpoint, and no posted results.
- GuideNCT05929066: what is the TRIUMPH-1 retatrutide trial?NCT05929066 is TRIUMPH-1, a Phase 3 retatrutide trial in obesity without type 2 diabetes. Registry status, enrolment, nested sub-studies, no posted results.
- GuideWhere does tirzepatide come from? Lilly's LY3298176Tirzepatide began as Eli Lilly's LY3298176, a synthetic 39-amino-acid peptide engineered on a GIP backbone. Whether it is a peptide or a hormone, and how it differs from semaglutide.
- GuideSURPASS and SURMOUNT: what the tirzepatide trials measuredSURPASS trials measured HbA1c in type 2 diabetes. SURMOUNT trials measured body weight. Two named tirzepatide programmes, two different questions.
- GuideRetatrutide in Australia: is it legal, approved or available yet?Retatrutide's approval and legal status in Australia and the US as of 14 October 2026: TGA statements, the Poisons Standard, the WADA list, the developer's submission plan, trial records and what is still unknown.
- GuideRetatrutide study findings: what do the clinical trials show?What published retatrutide trials found on weight, body fat, appetite and side effects, which registered trials are running in Australia, and what the studies do not show.
- GuideRetatrutide side effects: what trials and regulators have recordedThe side effects recorded in retatrutide trials, how often they occurred against placebo, serious events, and what Australian authorities have reported about products sold as retatrutide.
Citations
5 sourcesCoskun T et al. Cell Metabolism. 2022;34(9):1234-1247.e9.
doi:10.1016/j.cmet.2022.07.013Urva S et al. The Lancet. 2022;400:1869-1881.
doi:10.1016/S0140-6736(22)02033-5Jastreboff AM et al. New England Journal of Medicine. 2023;389(6):514-526.
doi:10.1056/NEJMoa2301972Rosenstock J et al. The Lancet. 2023;402:529-544.
doi:10.1016/S0140-6736(23)01053-XBajaj HS et al. The Lancet. 2026;407(10546):2402-2413.
doi:10.1016/S0140-6736(26)00967-0
Continue
Retatrutide reference materialResearch use only, not for human or animal use.
Read the retatrutide research guideForm Laboratories supplies research-use-only reference material. This article is an educational summary of published third-party literature. It is not medical advice, not a use instruction, and research material is not for human or animal use.
